BAFNA PHARMACEUTICALS LTD. - 532989 - Compliance Certificate For The Half Year Ended 31St March, 2019
Compliance Certificate certifying maintenance of physical and electronic transfer facility under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the half year ended 31st March, 2019 is hereby enclosed for your reference. Request you to take the same on record. Kindly acknowledge the receipt. BAFNA PHARMACEUTICALS LTD. - 532989 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
Further to our intimation vide our letter dated 11th March 2019, Please find attached updated order from NCLAT. This is for your information and record. NCLAT restricts handing over of Bafna Pharma to its promoter
If the possession has already been handed over, promoter will not alienate, transfer or create third-party encumbrance of properties and must ensure firm remains a going concern BAFNA PHARMACEUTICALS LTD. - 532989 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
Sub: National Company Law Appellate Tribunal, New Delhi Order Please find attached Order received by the Company from National Company Law Appellate Tribunal, New Delhi. This is for your information. BAFNA PHARMACEUTICALS LTD. - 532989 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
Sub: Implementation of the Resolution Plan / Capital Reduction This is in continuation of our earlier intimation dated 05th February 2019 regarding resolution plan which was approved by NCLT, Chennai vide its order dated 01st February 2019 under the Provisions of IBC, 2016. Pursuant to the Resolution Plan a capital reduction is proposed and the capital of the fully paid up equity shareholders shall be reduced to 10% and consequently the existing 2.36 Crores number of shares shall be reduced to 0.236 Crores. The Stock exchanges will be intimated in due course for effecting capital reduction. This is for your information and record. BAFNA PHARMACEUTICALS LTD. - 532989 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
Sub: Supervision of the Resolution Plan This is in continuation of our earlier intimation dated 05th February 2019 regarding resolution plan which was approved by NCLT, Chennai vide its order dated 01st February 2019 under the Provisions of IBC, 2016. Pursuant to the Resolution Plan a Monitoring Committee has been formed with the following members / representatives: Mr. Radhakrishnan Dharmarajan Mr. Spurgen David - Representative from SBI Mr. Nagabhusanam - Representative from IDBI Mr. M. Sridhar and Ms. S. Hemalatha - Representatives from Corporate Debtor Bafna Pharmaceuticals Ltd - 532989 - Results For The Third Quarter Ending 31St December 2018
We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the Third Quarter ending 31st December 2018. Please find attached the un-audited financial results for Third Quarter ending 31st December 2018 along with the Limited Review Report obtained from the statutory auditor of the Company. Bafna Pharmaceuticals Ltd - 532989 - Outcome of Board Meeting
We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the Third Quarter ending 31st December 2018. Please find attached the un-audited financial results for Third Quarter ending 31st December 2018 along with the Limited Review Report obtained from the statutory auditor of the Company. Appointment of Mr. Babulal Kamlesh Kumar (DIN: 01218959) as an Independent Director with effect from 08th February 2019 (Annexure-1) The meeting commenced at 3.00 PM and concluded at 6.45 P.M NCLT Chennai approves Bafna Pharmaceuticals' corporate insolvency resolution plan
City-based Bafna Pharmaceuticals today announced that Chennai bench of National Company Law Tribunal (NCLT) has approved the resolution plan submitted Bafna Pharmaceuticals Ltd - 532989 - Corporate Insolvency Resolution Process (CIRP)-Approval of Resolution plan by Tribunal
We refer to the ongoing CIRP of the company by which the Resolution Professional Mr. Radhakrishnan Dharmarajan, submitted the Resolution Plan approved by the COC (Meeting dated 04.01.2019) to the NCLT Chennai on 17.01.2019 for approval. We are pleased to announce that the Honorable NCLT Chennai Bench by its order dated 1st Feb 2019 ( received by the company on 4th Feb 2019) has approved the Resolution Plan submitted by Mr. BAFNA MAHAVEER CHAND (Resolution Applicant). The NCLT order is attached for your information.